And with a growing number of companies in the GLP-1 space, investors may be losing interest in the stock. Could Viking's ...

He told me about a patient who had recently benefited from his high blood pressure regulator herb and subsequently referred ...

LUND, SE / ACCESS Newswire / February 6, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) OCTOBER - DECEMBER IN BRIEF Net ...

Zimmer Biomet shares at $105 reveal value at 13 times adjusted earnings, as the company continues to grow despite a GLP-1 ...

Current Board’s Strategic, Management, and Capital Allocation Failures Have Driven an 80% Stock Decline Over Last 22 MonthsNew Leadership is ...

Global markets have recently experienced a mix of volatility and recovery, with U.S. stocks facing pressure from AI competition fears and mixed corporate earnings, while European indices benefited ...

Sales and operating profit growth, significant product acquisition signed October - December 2024 Consolidated sales during the third quarter, October to December amounted to SEK 92.2 (70.2) million ...

Public hearings will be held next week on contested charges filed by the Police Department against the borough's lone female ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

Though things are looking up for Akero, the stock still looks risky. Akero Therapeutics is developing efruxifermin as a ...